![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
674kB |
![[thumbnail of Supplementary Material]](https://edoc.mdc-berlin.de/style/images/fileicons/application_msword.png) |
MS Word (Supplementary Material)
686kB |
| Item Type: | Article |
|---|---|
| Title: | Pyridostigmine improves hand grip strength in patients with myalgic encephalomyelitis/chronic fatigue syndrome |
| Creators Name: | Schlömer, Ella, Stein, Elisa, Kedor, Claudia, Rust, Rebekka, Brock, Anna, Wittke, Kirsten, Scheibenbogen, Carmen and Kim, Laura |
| Abstract: | BACKGROUND: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a multisystemic disease characterized by exertional intolerance and fatigue which is often accompanied by muscle weakness and fatiguability. A study showed efficacy of the acetylcholinesterase inhibitor pyridostigmine on cardiac output in ME/CFS patients. Pyridostigmine is currently used off-label in ME/CFS and postural orthostatic tachycardia syndrome. METHODS: We evaluated the effect of pyridostigmine on hand grip strength in 20 patients with post-infectious ME/CFS. Hand grip strength testing was performed ten times using an electric dynamometer and was repeated after 1 h. In a second test, 30 mg of pyridostigmine was given immediately after the first measurement. Orthostatic function was assessed using a passive standing test. Neurological examination and autoantibody testing were performed to rule out a diagnosis of myasthenia gravis. RESULTS: All patients had reduced maximum hand grip strength with a median of 16.45 kg (IQR: 11.45 kg–22.8 kg). Hand grip strength was diminished by a median of 4.65 kg after 1 h. In contrast, 1 h after pyridostigmine administration, patients showed an improvement in maximum hand grip strength with a median increase of 2.6 kg. The maximum hand grip strength after exertion was about 1.5-fold higher with then without pyridostigmine (p = 0.01). The increase in heart rate from lying to standing was median 17 beats per minute without pyridostigmine (IQR: 13 beats per minute – 23 beats per minute) and 13 beats per minute (IQR: 9 beats per minute – 20 beats per minute) (p = 0.017) with pyridostigmine. None of the patients tested positive for myasthenia gravis specific autoantibodies. CONCLUSION: Pyridostigmine exerts an immediate effect on muscle strength and orthostatic function. This may be attributed to increased acetylcholine availability at neuromuscular junctions, and its augmentation of parasympathetic tone. |
| Keywords: | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Post-COVID Syndrome, Hand Grip Strength, Orthostatic Intolerance, Myasthenia Gravis, COVID-19, Pyridostigmine |
| Source: | Frontiers in Neuroscience |
| ISSN: | 1662-453X |
| Publisher: | Frontiers Media SA |
| Volume: | 19 |
| Page Range: | 1637838 |
| Date: | 3 September 2025 |
| Official Publication: | https://doi.org/10.3389/fnins.2025.1637838 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
